I would say there is some doubt about the trial completing by mid-year, there has already been delays. They haven't given any clear comment on the current status in terms of numbers already completed and currently being dosed. That said I'm not expecting it to be a significant issue. More uncertainty in my mind comes from CUV107 and what the deal is with that? What will determine if it's needed, how does it differ from CUV105 and what will it mean to a date when Scenesse can actually be filed for approval to use in Vitiligo?
I would say there is some doubt about the trial completing by...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.43 |
Change
-0.540(4.16%) |
Mkt cap ! $623.0M | |||
| Open | High | Low | Value | Volume |
| $13.02 | $13.18 | $12.26 | $1.408M | 112.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 688 | $12.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.45 | 3234 | 2 |
View Market Depth
| Last trade - 16.10pm 01/08/2025 (20 minute delay) ? |
| CUV (ASX) Chart |